Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05469048 · ClinicalTrials.gov registry record

Near Patient Molecular Testing in Sepsis

A clinical trial, sponsored by Immunexpress.

Completed
Registry status
63
Enrollment target

NCT05469048 is a clinical trial that has completed, run by Immunexpress. The registered enrollment target is 63 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05469048 has completed, sponsored by Immunexpress.

COMPLETED
Registry status
63 participants
Enrollment target

Study Summary

The purpose of the study is to evaluate the real-time performance of a new host response test (SeptiCyte RAPID) for differentiating sepsis from non-infection/systemic inflammatory response syndrome among patients suspected of sepsis within the first 24 hours of intensive care unit (ICU) admission.

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2020-03-12
Est. Completion 2022-10-31

Sponsor

Immunexpress

3 total trials

What the Registry Record Tells You About NCT05469048

The ClinicalTrials.gov registry entry for NCT05469048 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunexpress, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT05469048 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05469048 about?

NCT05469048 is a clinical study titled "Near Patient Molecular Testing in Sepsis". The purpose of the study is to evaluate the real-time performance of a new host response test (SeptiCyte RAPID) for differentiating sepsis from non-infection/systemic inflammatory response syndrome among patients suspected of sepsis within the first 24 hours of intensive care unit (ICU) admission.

What is the current status of trial NCT05469048?

This trial is currently completed. The enrollment target is 63 participants. The study started on 2020-03-12. Estimated completion is 2022-10-31.

Who is sponsoring clinical trial NCT05469048?

This trial is sponsored by Immunexpress, which has 3 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.